Actively Recruiting
Safety Evaluation of Inhaled TQC3721 Suspension in Moderate to Severe COPD Patients Using Nebulized Treatment
Led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Updated on 2026-09-28
800
Participants Needed
54
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety of inhaled TQC3721 suspension, a Phosphodiesterase34 inhibitor, in patients with moderate to severe Chronic Obstructive Pulmonary Disease COPD. This phase 3 study aims to observe adverse effects and lung function changes, providing valuable information about the treatment in this patient group. Participants receive TQC3721 suspension via inhalation at a dose of 6mg2ml twice daily. Two groups are studied one group uses the suspension for 24 weeks, and the other for 12 weeks. The study includes an extended observation period for safety in the longer treatment group. During the trial, participants undergo lung function tests measuring the forced expiratory volume in 1 second FEV1, and lab tests to monitor for adverse events and abnormalities. The study tracks COPD exacerbations and other health changes for up to 48 weeks. Participants are monitored regularly to assess treatment safety and lung function over time.
CONDITIONS
Brief Title
Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
Research Team
W
Weimin Li, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here